News
More NewsERN RARE-LIVER Study - Survey for people with PSC, PBC or AIH
Social determinants of health (SDOH) are the conditions in which people are born, grow up, work and age. Studies suggest that SDOH influence the course of liver disease. However, this has not yet been studied in patients with autoimmune liver disease.
ERN RARE-LIVER Members' Meeting 23 + 24 January 2025
Save the date for our Members’ Meeting in Barcelona on 23 + 24 January 2025.
Participation is limited to two representatives per member centre, including affiliated partners. One of the participants can be funded per centre, according to EC regulations (EU unit costs).
Ocaliva for PBC - FDA Advisory Panel Voting, 13 September 2024
On 13 September 2024, a meeting of the Gastrointestinal Drugs Advisory Committee took place at which supplemental New Drug Application (sNDA) 207999 S-011, for OCALIVA (obeticholic acid) was discussed. The meeting was open to the public and was streamed live on the official FDA YouTube channel.
ERN RARE-LIVER EASL ACADEMY 2025
The ERN RARE-LIVER EASL ACADEMY 2025 will be hosted by the university hospital of Heidelberg and will focus on rare liver diseases with special focus on translating clinical practice guidelines in real-life care.
Veselina has had AIH since the age of three
Please watch our new video describing Veselinas path and experience with the right treatment of her diagnosis.
Tips how to take medication regularly
These tips are a team effort by Aida Regi Cosculluela and Dr Wiebke Papenthin,
named patient representatives of the ERN RARE-LIVER Wilson working group and the ERN Youth Panel.
Scientific News
More Scientific NewsNew ERN RARE-LIVER Paper on PSVD - Journal of Hepatology
Porto-sinusoidal vascular liver disorder (PSVD) is a rare liver condition that often leads to severe complications from portal hypertension and can reduce life expectancy.
For Physicians: New ERN RARE-LIVER Survey on Alcohol Use
ERN RARE-LIVER has constructed the survey “Counselling Young Adults With Liver Disease On Alcohol Use”. The survey will be open until 8 September, 2024. It consists of max. 10 pages and it will take 10 to 15 minutes to respond.
Open letter to the European Commision
The rare disease community comes together in calling on the EU institutions and our national governments to stand by the European Reference Networks.
COST ACTION EURO-VALDI-NET accepted
Congratulations to Pierre-Emmanuel Rautou and colleagues for their successful COST Action application! 134 researchers from 27 countries put together the EURO-VALDI-NET project on vascular liver diseases.